诚意药业(603811) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥165,864,539.28, representing a decrease of 8.97% compared to the same period last year[5] - Net profit attributable to shareholders was ¥39,750,798.15, showing a slight increase of 0.69% year-on-year[5] - The basic earnings per share for the quarter was ¥0.17, with a year-to-date figure of ¥0.51, reflecting a 15.91% increase[7] - The net profit attributable to shareholders for the year-to-date was ¥118,099,843.50, an increase of 14.96% compared to the same period last year[5] - In Q3 2021, the company's net profit reached CNY 118,457,818.07, an increase of 15.4% compared to CNY 102,886,721.91 in Q3 2020[22] - The company's operating profit for Q3 2021 was CNY 140,375,076.96, up from CNY 121,824,787.04 in Q3 2020, indicating a year-over-year increase of 15.2%[22] - The company reported a total comprehensive income of CNY 118,461,416.90 in Q3 2021, compared to CNY 102,746,318.20 in Q3 2020, representing a growth of 15.2%[23] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,241,285,980.39, an increase of 2.85% from the end of the previous year[7] - Total assets amounted to ¥1,241,285,980.39, compared to ¥1,206,881,405.82, representing an increase of about 2.8%[18] - Total liabilities decreased to ¥295,184,614.86 from ¥320,794,257.19, indicating a reduction of approximately 8.0%[18] - The company's equity attributable to shareholders increased to ¥933,606,736.59 from ¥873,950,854.14, reflecting a growth of about 6.8%[18] Cash Flow and Investments - The company reported a cash flow from operating activities of ¥91,717,153.63 for the year-to-date, which is a decrease of 13.76%[7] - The cash flow from operating activities for the first nine months of 2021 was CNY 91,717,153.63, down from CNY 106,345,768.07 in the same period of 2020, a decrease of 13.8%[26] - The net cash flow from investing activities was negative CNY 34,774,285.52 in Q3 2021, compared to negative CNY 276,360,741.35 in Q3 2020, showing an improvement[27] Shareholder Information - The company had a total of 15,186 common shareholders at the end of the reporting period[12] - The largest shareholder, Yan Yiyi, holds 23.58% of the shares, totaling 55,137,200 shares[12] Operating Costs and Revenue - Total operating revenue for the first three quarters of 2021 reached ¥523,732,179.68, an increase from ¥512,332,595.93 in the same period of 2020, representing a growth of approximately 4.1%[21] - Total operating costs decreased to ¥404,496,899.28 from ¥416,303,868.11, indicating a reduction of about 2.0%[21] Other Financial Metrics - The weighted average return on equity decreased to 4.35%, down 0.6 percentage points from the previous year[7] - Research and development expenses increased to CNY 29,531,472.54 in Q3 2021 from CNY 23,331,609.70 in Q3 2020, marking a rise of 26.6%[22] - Financial expenses decreased to CNY 871,393.84 in Q3 2021 from CNY 1,953,497.81 in Q3 2020, a reduction of 55.5%[22] - Short-term borrowings rose significantly to ¥89,410,653.59 from ¥40,043,000.00, an increase of approximately 123.5%[17] Accounts Receivable and Inventory - Accounts receivable rose to ¥81,328,166.34, up from ¥66,344,156.94, marking an increase of about 22.6%[16] - Inventory decreased to ¥103,208,855.86 from ¥119,256,476.27, showing a decline of approximately 13.5%[16]